Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium.
Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC. Lobbezoo DJ, et al. Among authors: van kampen rj, van de wouw aj, de boer m, van riel jm, van den berkmortel f. Ann Oncol. 2016 Feb;27(2):256-62. doi: 10.1093/annonc/mdv544. Epub 2015 Nov 16. Ann Oncol. 2016. PMID: 26578730 Free article.
Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
van Nes JG, Seynaeve C, Maartense E, Roumen RM, de Jong RS, Beex LV, Meershoek-Klein Kranenbarg WM, Putter H, Nortier JW, van de Velde CJ; Cooperating investigators of the Dutch TEAM trial. van Nes JG, et al. Ann Oncol. 2010 May;21(5):974-82. doi: 10.1093/annonc/mdp419. Epub 2009 Oct 29. Ann Oncol. 2010. PMID: 19875752 Free article. Clinical Trial.
Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Borm GF, Tjan-Heijnen VC. Aarts MJ, et al. Among authors: van laarhoven hw, van de wouw aj, van warmerdam lj, van der rijt cc, van gastel sm, van der velden aw. J Clin Oncol. 2013 Dec 1;31(34):4290-6. doi: 10.1200/JCO.2012.44.6229. Epub 2013 Apr 29. J Clin Oncol. 2013. PMID: 23630211 Clinical Trial.
Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Borm GF, Tjan-Heijnen VC. Lobbezoo DJ, et al. Among authors: van kampen rj, van de wouw aj, de boer m, van riel jm, van den berkmortel f. Breast Cancer Res Treat. 2013 Oct;141(3):507-14. doi: 10.1007/s10549-013-2711-y. Epub 2013 Oct 9. Breast Cancer Res Treat. 2013. PMID: 24104881
Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Joore MA, Borm GF, Tjan-Heijnen VC. Aarts MJ, et al. Among authors: van laarhoven hw, van de wouw aj, van warmerdam lj, van der rijt cc, van gastel sm, van der velden aw. J Clin Oncol. 2013 Dec 1;31(34):4283-9. doi: 10.1200/JCO.2012.48.3644. Epub 2013 Oct 28. J Clin Oncol. 2013. PMID: 24166522 Clinical Trial.
Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC. Lobbezoo DJ, et al. Among authors: van kampen rj, van de wouw aj, de boer m, van riel jm, van den berkmortel f. Br J Cancer. 2015 Apr 28;112(9):1445-51. doi: 10.1038/bjc.2015.127. Epub 2015 Apr 16. Br J Cancer. 2015. PMID: 25880008 Free PMC article.
Patients' Preferences for Information About the Benefits and Risks of Second-Line Palliative Chemotherapy and Their Oncologist's Awareness of These Preferences.
Oostendorp LJ, Ottevanger PB, van de Wouw AJ, Honkoop AH, Los M, van der Graaf WT, Stalmeier PF. Oostendorp LJ, et al. Among authors: van de wouw aj, van der graaf wt. J Cancer Educ. 2016 Sep;31(3):443-8. doi: 10.1007/s13187-015-0845-9. J Cancer Educ. 2016. PMID: 25985960 Free PMC article. Clinical Trial.
70 results